REGENXBIO (RGNX) Competitors $8.47 -0.07 (-0.82%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RGNX vs. EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, NTLA, and TVTXShould you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Intellia Therapeutics (NTLA), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. REGENXBIO vs. Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Intellia Therapeutics Travere Therapeutics REGENXBIO (NASDAQ:RGNX) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Which has more volatility & risk, RGNX or EVO? REGENXBIO has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Does the media refer more to RGNX or EVO? In the previous week, REGENXBIO had 3 more articles in the media than Evotec. MarketBeat recorded 6 mentions for REGENXBIO and 3 mentions for Evotec. Evotec's average media sentiment score of 0.65 beat REGENXBIO's score of 0.56 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in RGNX or EVO? 88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, RGNX or EVO? Evotec has higher revenue and earnings than REGENXBIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$84.33M4.98-$263.49M-$5.03-1.68Evotec$777.05M2.18-$90.82MN/AN/A Is RGNX or EVO more profitable? Evotec has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Evotec's return on equity of 0.00% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Evotec N/A N/A N/A Do analysts prefer RGNX or EVO? REGENXBIO presently has a consensus price target of $35.27, indicating a potential upside of 316.44%. Evotec has a consensus price target of $5.93, indicating a potential upside of 24.13%. Given REGENXBIO's stronger consensus rating and higher possible upside, research analysts plainly believe REGENXBIO is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community prefer RGNX or EVO? REGENXBIO received 430 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 65.96% of users gave REGENXBIO an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes43665.96% Underperform Votes22534.04% EvotecOutperform Votes654.55% Underperform Votes545.45% SummaryREGENXBIO beats Evotec on 9 of the 16 factors compared between the two stocks. Ad True Market InsidersHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…#1 FREE Crypto for 2024 Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGNX vs. The Competition Export to ExcelMetricREGENXBIOBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$419.65M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-1.6847.02135.1917.53Price / Sales4.98420.131,224.59140.21Price / CashN/A182.1340.6537.95Price / Book1.193.924.884.92Net Income-$263.49M-$42.03M$118.97M$225.78M7 Day Performance-8.92%-3.37%15.53%-1.58%1 Month Performance-16.55%7.95%15.54%6.67%1 Year Performance-56.59%21.00%34.63%22.48% REGENXBIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGNXREGENXBIO4.6182 of 5 stars$8.47-0.8%$35.27+316.4%-57.6%$419.65M$84.33M-1.68344EVOEvotec1.4795 of 5 stars$4.69+4.5%$5.93+26.5%-56.6%$1.66B$777.05M0.005,061Short Interest ↓ARQTArcutis Biotherapeutics0.8059 of 5 stars$13.34+5.1%$15.50+16.2%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageNRIXNurix Therapeutics2.8431 of 5 stars$21.19+4.5%$30.35+43.2%+133.3%$1.50B$56.42M-6.97300RCUSArcus Biosciences2.7843 of 5 stars$16.25+1.1%$34.00+109.2%-11.3%$1.49B$117M-5.11500KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.40+1.0%$36.60+79.4%+13.9%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.6216 of 5 stars$29.05+0.5%$65.64+125.9%-54.2%$1.45B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$8.98+3.3%$16.71+86.1%+129.5%$1.41B$58.44M0.00267Positive NewsMESOMesoblast1.2998 of 5 stars$12.18+3.6%$11.50-5.6%+484.6%$1.39B$5.90M0.0080News CoverageGap UpNTLAIntellia Therapeutics4.1809 of 5 stars$13.50+4.7%$54.94+306.9%-57.3%$1.37B$36.28M-2.37600Short Interest ↑TVTXTravere Therapeutics2.7223 of 5 stars$17.54+1.3%$22.62+28.9%+97.9%$1.37B$145.24M-3.81460Positive News Related Companies and Tools Related Companies EVO Alternatives ARQT Alternatives NRIX Alternatives RCUS Alternatives KNSA Alternatives IMCR Alternatives OCUL Alternatives MESO Alternatives NTLA Alternatives TVTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RGNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
